Mankind Pharma Limited Q2 FY27 Results: Net Profit ₹716 cr, Revenue from operations ₹4,338 cr
Quick answer
Mankind Pharma Limited (MANKIND) reported Consolidated Q2 FY27 revenue from operations of ₹4,338 cr and net profit of ₹716 cr. Official figures, comparisons and disclosure details.
Figures are from the company's reported results for the stated period; year-on-year comparisons use the same quarter of the previous year.
Quick summary
Revenue
₹4,338 cr
Net Profit
₹716 cr
Mankind Pharma Limited has filed its Consolidated financial results for the quarter ended 2026-09-30 with NSE. Revenue from operations was ₹4,338 cr, while net profit stood at ₹716 cr. These are reported statement figures, not estimates or a board-meeting announcement.
Official Q2 FY27 scorecard
All amounts are in ₹ crore, except per-share earnings in rupees. A dash means the corresponding figure was not verified in this statement.
| Metric | Q2 FY27 | Previous quarter | Year-ago quarter | QoQ | YoY |
|---|---|---|---|---|---|
| Revenue from operations | ₹4,338 cr | — | — | — | — |
| Total expenses | ₹3,507 cr | — | — | — | — |
| Profit before tax | ₹925 cr | — | — | — | — |
| Tax expense | ₹213 cr | — | — | — | — |
| Finance costs | ₹105 cr | — | — | — | — |
| Net profit / loss | ₹716 cr | — | — | — | — |
| Basic EPS | ₹17.23 | — | — | — | — |
Revenue and profit comparison
A matching year-ago quarterly statement was not verified in this filing, so a year-on-year comparison is not reported. The immediately preceding quarter was not verified; no sequential growth figure has been inferred from cumulative half-year or annual totals. Percentage changes use the absolute prior-period value; movement from a loss is not described as ordinary profit growth.
Profitability and earnings quality
Net profit/loss divided by revenue gives a net margin of +16.5%. Profit before tax was ₹925 cr. Reported basic EPS was ₹17.23. These figures alone do not establish the cause of a margin change; operating leverage, exceptional items and demand explanations require the company's disclosures.
Reporting basis and disclosure checks
This report uses Consolidated figures only; standalone and consolidated statements are not combined. The reporting period ends on 2026-09-30; the exchange records the filing time as 26-Oct-2026 21:18:11. The quarter-end date is not the announcement date. Segment performance, cash flow, debt, exceptional items, dividend decisions, auditor qualifications and management guidance are not asserted where the structured filing has not verified them. Read the attached official statement and notes before drawing conclusions.
What to track after the result
Compare future revenue, earnings and margins on the same reporting basis and accounting period. Check the official notes for restatements and non-recurring items; a quarterly profit number is not a share-price forecast. No live share-price reaction, analyst consensus, dividend or guidance is inferred from these statement figures.
Sources
Disclosure: Financial information and analysis only; not investment advice. Official filings can be amended; missing or unsupported fields are not estimated.
Frequently asked questions
Why is MANKIND in the news today?
Mankind Pharma Limited (MANKIND) reported Consolidated Q2 FY27 revenue from operations of ₹4,338 cr and net profit of ₹716 cr. Official figures, comparisons and disclosure details.
What do the numbers in official Q2 FY27 scorecard show?
All amounts are in ₹ crore, except per-share earnings in rupees. A dash means the corresponding figure was not verified in this statement.
What stood out in revenue and profit comparison?
A matching year-ago quarterly statement was not verified in this filing, so a year-on-year comparison is not reported. The immediately preceding quarter was not verified; no sequential growth figure has been inferred from cumulative half-year or annual totals.
How did profitability and earnings quality perform this quarter?
Net profit/loss divided by revenue gives a net margin of +16.5%. Profit before tax was ₹925 cr. Reported basic EPS was ₹17.23. These figures alone do not establish the cause of a margin change; operating leverage, exceptional items and demand explanations require the company's disclosures.
What is happening with reporting basis and disclosure checks?
This report uses Consolidated figures only; standalone and consolidated statements are not combined. The reporting period ends on 2026-09-30; the exchange records the filing time as 26-Oct-2026 21:18:11. The quarter-end date is not the announcement date.
What to track after the result?
Compare future revenue, earnings and margins on the same reporting basis and accounting period. Check the official notes for restatements and non-recurring items; a quarterly profit number is not a share-price forecast.
Comments
Comments are moderated. Be civil, no stock tips or promotions.
Loading comments…
Written by TrendRipperX Data Desk. Figures come from exchange, company and market-data sources linked in the story. Spotted an error? Tell the newsroom — see our corrections policy and editorial policy.
For information only, not investment advice. TrendRipperX is not a SEBI-registered adviser. Full disclaimer.
Related articles
Canara Bank Q2 FY27 Results: Net Profit ₹5,175 cr, Revenue from operations ₹35,159 cr
Canara Bank (CANBK) reported Standalone Q2 FY27 revenue from operations of ₹35,159 cr and net profit of ₹5,175 cr. Official figures, comparisons and disclosure details.
Indian Bank Q2 FY27 Results: Net Profit ₹3,462 cr, Revenue from operations ₹19,106 cr
Indian Bank (INDIANB) reported Standalone Q2 FY27 revenue from operations of ₹19,106 cr and net profit of ₹3,462 cr. Official figures, comparisons and disclosure details.
Punjab National Bank Q2 FY27 Results: Net Profit ₹5,532 cr, Revenue from operations ₹34,585 cr
Punjab National Bank (PNB) reported Standalone Q2 FY27 revenue from operations of ₹34,585 cr and net profit of ₹5,532 cr. Official figures, comparisons and disclosure details.
Newsletter